Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. Devos D; Moreau C; Maltete D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destee A; Duhamel A; Bordet R; Defebvre L; and Dujardin K J. Neurol. Neurosurg. Psychiatry, 85:668-674, 2014.
Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial [link]Paper  doi  bibtex   
@article{devos_d_rivastigmine_2014,
title = {Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial},
volume = {85},
issn = {0022-3050},
url = {http://www.ncbi.nlm.nih.gov/pubmed/24218528},
DOI = {10.1136/jnnp-2013-306439},
Language = {English},
Journal = {J. Neurol. Neurosurg. Psychiatry},
author = {{Devos D} and {Moreau C} and {Maltete D} and {Lefaucheur R} and {Kreisler A} and {Eusebio A} and {Defer G} and {Ouk T} and {Azulay JP} and {Krystkowiak P} and {Witjas T} and {Delliaux M} and {Destee A} and {Duhamel A} and {Bordet R} and {Defebvre L} and {Dujardin K}},
year = {2014},
keywords = {Activities of Daily Living, Adult, Aged, Apathy*, Cholinesterase Inhibitors/therapeutic use*, Dementia/diagnosis, Depression/diagnosis, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuroprotective Agents/therapeutic use*, Parkinson Disease/drug therapy*, Parkinson Disease/psychology*, Phenylcarbamates/therapeutic use*, Prospective Studies, Rivastigmine, Severity of Illness Index},
pages = {668-674}
}
Downloads: 0